Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02601950
Title A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

rhabdoid cancer

synovial sarcoma

Advanced Solid Tumor

Therapies

Tazemetostat

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | CAN | BEL


No variant requirements are available.